New Malaria Vaccine Trial Shows 87% Efficacy
A genetically engineered malaria vaccine protected 13 of 15 volunteers in a small phase 1 trial — 87% efficacy. The results were presented on 19 November 2026.
N
Newsy Desk
Nov 21, 2026